These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37664462)

  • 1. Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata.
    Ulm JW; Barthélémy F; Nelson SF
    Front Cell Dev Biol; 2023; 11():1226707. PubMed ID: 37664462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy.
    Botti V; Menzel O; Staedler D
    Front Pharmacol; 2022; 13():1030785. PubMed ID: 36467064
    [No Abstract]   [Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for selected neuromuscular and trinucleotide repeat disorders - An insight to subsume South Asia for multicenter clinical trials.
    Wijekoon N; Gonawala L; Ratnayake P; Sirisena D; Gunasekara H; Dissanayake A; Senanayake S; Keshavaraj A; Hathout Y; Steinbusch HWM; Mohan C; Dalal A; Hoffman E; D de Silva KR
    IBRO Neurosci Rep; 2023 Jun; 14():146-153. PubMed ID: 36819775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel chemical-combination screen in zebrafish identifies epigenetic small molecule candidates for the treatment of Duchenne muscular dystrophy.
    Farr GH; Morris M; Gomez A; Pham T; Kilroy E; Parker EU; Said S; Henry C; Maves L
    Skelet Muscle; 2020 Oct; 10(1):29. PubMed ID: 33059738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genetic analysis of 961 unrelated Duchenne Muscular Dystrophy patients: Focus on diagnosis, prevention and therapeutic possibilities.
    Kumar SH; Athimoolam K; Suraj M; Das Christu Das MS; Muralidharan A; Jeyam D; Ashokan J; Karthikeyan P; Krishna R; Khanna-Gupta A; Bremadesam Raman L
    PLoS One; 2020; 15(6):e0232654. PubMed ID: 32559196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy.
    Lai X; Chen J
    Bioengineered; 2021 Dec; 12(1):5428-5439. PubMed ID: 34424816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
    Gatheridge MA; Kwon JM; Mendell JM; Scheuerbrandt G; Moat SJ; Eyskens F; Rockman-Greenberg C; Drousiotou A; Griggs RC
    JAMA Neurol; 2016 Jan; 73(1):111-6. PubMed ID: 26594870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duchenne muscular dystrophy hiPSC-derived myoblast drug screen identifies compounds that ameliorate disease in mdx mice.
    Sun C; Choi IY; Rovira Gonzalez YI; Andersen P; Talbot CC; Iyer SR; Lovering RM; Wagner KR; Lee G
    JCI Insight; 2020 Jun; 5(11):. PubMed ID: 32343677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free intramuscular Mg
    Reyngoudt H; Lopez Kolkovsky AL; Carlier PG
    NMR Biomed; 2019 Sep; 32(9):e4115. PubMed ID: 31184793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring Duchenne muscular dystrophy impact: development of a proxy-reported measure derived from PROMIS item banks.
    Schwartz CE; Stark RB; Cella D; Borowiec K; Gooch KL; Audhya IF
    Orphanet J Rare Dis; 2021 Nov; 16(1):487. PubMed ID: 34809687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exons 45-55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells.
    He M; Yokota T
    Methods Mol Biol; 2023; 2640():313-325. PubMed ID: 36995604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newborn Screening for Duchenne Muscular Dystrophy: First Year Results of a Population-Based Pilot.
    Hartnett MJ; Lloyd-Puryear MA; Tavakoli NP; Wynn J; Koval-Burt CL; Gruber D; Trotter T; Caggana M; Chung WK; Armstrong N; Brower AM
    Int J Neonatal Screen; 2022 Sep; 8(4):. PubMed ID: 36278620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons from an Experiential Approach to Patient Community Engagement in Rare Disease.
    Smith J; Damm K; Hover G; Chien J
    Clin Ther; 2021 Feb; 43(2):421-429. PubMed ID: 33375998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.
    Kornegay JN; Spurney CF; Nghiem PP; Brinkmeyer-Langford CL; Hoffman EP; Nagaraju K
    ILAR J; 2014; 55(1):119-49. PubMed ID: 24936034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United States.
    Thayer S; Bell C; McDonald CM
    J Manag Care Spec Pharm; 2017 Jun; 23(6):633-641. PubMed ID: 28530521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
    Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
    BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying FDA-Approved Drugs that Upregulate Utrophin A as a Therapeutic Strategy for Duchenne Muscular Dystrophy.
    Péladeau C; Jasmin BJ
    Methods Mol Biol; 2023; 2587():495-510. PubMed ID: 36401046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
    Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
    Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.